These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 24717047)
21. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations. Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042 [TBL] [Abstract][Full Text] [Related]
22. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas. Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465 [TBL] [Abstract][Full Text] [Related]
23. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours. Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464 [TBL] [Abstract][Full Text] [Related]
24. Stable genetic alterations of β-catenin and ROR2 regulate the Wnt pathway, affect the fate of MSCs. Cai SX; Liu AR; He HL; Chen QH; Yang Y; Guo FM; Huang YZ; Liu L; Qiu HB J Cell Physiol; 2014 Jun; 229(6):791-800. PubMed ID: 24590964 [TBL] [Abstract][Full Text] [Related]
25. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480 [TBL] [Abstract][Full Text] [Related]
26. Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. Lepreux S; Rebouissou S; Le Bail B; Saric J; Balabaud C; Bloch B; Martin-Négrier ML; Zucman-Rossi J; Bioulac-Sage P J Hepatol; 2005 Mar; 42(3):424-9. PubMed ID: 15710230 [TBL] [Abstract][Full Text] [Related]
27. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872 [TBL] [Abstract][Full Text] [Related]
28. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897 [TBL] [Abstract][Full Text] [Related]
29. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912 [TBL] [Abstract][Full Text] [Related]
30. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Gaujoux S; Grabar S; Fassnacht M; Ragazzon B; Launay P; Libé R; Chokri I; Audebourg A; Royer B; Sbiera S; Vacher-Lavenu MC; Dousset B; Bertagna X; Allolio B; Bertherat J; Tissier F Clin Cancer Res; 2011 Jan; 17(2):328-36. PubMed ID: 21088256 [TBL] [Abstract][Full Text] [Related]
38. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Doghman M; Cazareth J; Lalli E J Clin Endocrinol Metab; 2008 Aug; 93(8):3222-5. PubMed ID: 18544621 [TBL] [Abstract][Full Text] [Related]
39. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas. Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497 [No Abstract] [Full Text] [Related]
40. beta-Catenin nuclear accumulation in head and neck mucoepidermoid carcinoma: its role in cyclin D1 overexpression and tumor progression. Shiratsuchi H; Nakashima T; Hirakawa N; Toh S; Nakagawa T; Saito T; Tsuneyoshi M; Komune S Head Neck; 2007 Jun; 29(6):577-84. PubMed ID: 17315172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]